What is the role of aspirin in the management of a patient undergoing percutaneous coronary intervention?

The role of aspirin in the management of a patient undergoing percutaneous coronary intervention (PCI) is pivotal due to its antiplatelet properties. Administering aspirin before and continuing after PCI helps to reduce the risk of thrombotic events, such as stent thrombosis and myocardial infarction, which can occur following the procedure.

Aspirin works by inhibiting the cyclooxygenase (COX) enzyme, leading to a decrease in the production of thromboxane A2, a potent platelet aggregator. This makes aspirin a cornerstone therapy in the context of PCI, as it helps to stabilize the newly placed stents and minimizes the likelihood of blood clot formation at the site of intervention.

Furthermore, guidelines typically recommend initiating aspirin therapy before the procedure and maintaining it long-term, unless contraindications arise. This long-term use is crucial for patients with coronary artery disease or those who have undergone stenting, as it provides ongoing protection against future thrombotic complications.

Therefore, the administration of aspirin both before and after PCI reflects current clinical practice and evidence supporting its effectiveness in enhancing patient outcomes.